IFN-γ-mediated anti-oncogenic functions are well demonstrated in cancer, including in lung cancer, and exogenous administration has been used to treat different malignancies and PTEN appears to play a role also in the IFN-γ impact. The gene discussed is IFNG; the disease is lung carcinoma.